$1.50
+0.04 (+2.74%)
Open$1.45
Previous Close$1.46
Day High$1.52
Day Low$1.43
52W High$9.88
52W Low$4.56
Volume—
Avg Volume504.4K
Market Cap158.02M
P/E Ratio57.36
EPS$0.12
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+513.3% upside
Current
$1.50
$1.50
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 53.23M | 53.79M | 56.60M |
| Net Income | 2.83M | 2.31M | 2.33M |
| Profit Margin | 5.3% | 4.3% | 4.1% |
| EBITDA | 4.51M | 4.13M | 4.65M |
| Free Cash Flow | 2.47M | 1.88M | 2.75M |
| Rev Growth | +4.7% | +4.8% | +15.4% |
| Debt/Equity | 0.16 | 0.17 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |